Sodium Channel Protein Type IV Subunit Alpha (SCN4A): A Potential Drug Target and Biomarker

Target Name: SCN4A

NCBI ID: G6329

Sodium Channel Protein Type IV Subunit Alpha (SCN4A): A Potential Drug Target and Biomarker

Abstract:
Sodium channel protein type IV subunit alpha (SCN4A) is a protein that plays a crucial role in the regulation of neural and cardiac function. Abnormalities in SCN4A levels or function have been implicated in a variety of neurological and cardiovascular disorders. As a result, targeting SCN4A has emerged as a promising strategy for the development of new therapeutic approaches. In this article, we will discuss the current understanding of SCN4A, its function in neural and cardiac systems, its potential as a drug target, and its potential as a biomarker for various neurological and cardiovascular disorders.

Introduction:
Sodium channel proteins are a family of transmembrane proteins that play a central role in the regulation of ion traffic and membrane potential. The sodium channel protein type IV subunit alpha (SCN4A) is a key member of this family, and its function in neural and cardiac systems has been extensively studied. SCN4A is a 120-kDa protein that is expressed in high levels in the heart, brain, and other neural tissues. It is involved in the regulation of Na+ and K+ ion channels, which are critical for the maintenance of membrane potential and the proper functioning of neural and cardiac cells.

Function and Interactions:
SCN4A is a critical protein for maintaining the resting membrane potential of neural and cardiac cells. It plays a key role in the regulation of Na+ and K+ ion channels, allowing it to maintain the stability of the cell's membrane potential. In addition, SCN4A is involved in the regulation of other membrane proteins, including the myosin ATPase. This protein is responsible for generating the energy that the muscle contractions require, and its activity is regulated by various factors, including sodium ions.

SCN4A dysfunction has been implicated in a variety of neurological and cardiovascular disorders, including epilepsy, bipolar disorder, and heart failure. Studies have shown that individuals with genetic mutations that affect SCN4A function are at increased risk for developing these disorders. Additionally, altered levels of SCN4A have been observed in a variety of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Drug Targeting:
The potential drug targeting of SCN4A is due to its unique function in the regulation of neural and cardiac systems. Drugs that can modulate SCN4A function have the potential to treat a variety of neurological and cardiovascular disorders. For example, inhibitors of SCN4A have been shown to be effective in treating epilepsy, bipolar disorder, and heart failure. Additionally, modulators of SCN4A have been shown to be effective in treating neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Biomarker Potential:
SCN4A may also have potential as a biomarker for various neurological and cardiovascular disorders. Changes in SCN4A levels or function have been observed in a variety of disorders, including neurological and cardiovascular disease. For example, altered levels of SCN4A have been observed in individuals with Alzheimer's disease, and individuals with certain genetic mutations that affect SCN4A function are at increased risk for developing these disorders. Additionally, SCN4A levels have been shown to be altered in individuals with heart failure, and these changes may be a sign of underlying SCN4A dysfunction.

Conclusion:
In conclusion, SCN4A is a protein that plays a crucial role in the regulation of neural and cardiac function. Its function in maintaining the resting membrane potential of neural and cardiac cells and its involvement in the regulation of Na+ and K+ ion channels make it an attractive target for drug targeting. Additionally, its potential as a biomarker for various neurological and cardiovascular disorders makes it an important compound to study in the development of new therapeutic approaches. Further research is needed to fully understand the role of SCN4A in neural and cardiac systems and its potential as a drug target and biomarker.

Protein Name: Sodium Voltage-gated Channel Alpha Subunit 4

Functions: Pore-forming subunit of a voltage-gated sodium channel complex through which Na(+) ions pass in accordance with their electrochemical gradient. Alternates between resting, activated and inactivated states (PubMed:12766226, PubMed:29992740, PubMed:30190309, PubMed:15318338, PubMed:16890191, PubMed:18690054, PubMed:17898326, PubMed:19347921, PubMed:25707578, PubMed:26700687). Required for normal muscle fiber excitability, normal muscle contraction and relaxation cycles, and constant muscle strength in the presence of fluctuating K(+) levels (PubMed:12766226, PubMed:15318338, PubMed:16890191, PubMed:19347921, PubMed:25707578, PubMed:26700687, PubMed:26659129)

More Common Targets